Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Identifieur interne : 000500 ( Main/Exploration ); précédent : 000499; suivant : 000501Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Auteurs : Benjamin Davido [France] ; Ghilas Boussaid [France] ; Isabelle Vaugier [France] ; Thibaud Lansaman [France] ; Frédérique Bouchand [France] ; Christine Lawrence [France] ; Jean-Claude Alvarez [France] ; Pierre Moine [France] ; Véronique Perronne [France] ; Frédéric Barbot [France] ; Azzam Saleh-Mghir [France] ; Christian Perronne [France] ; Djillali Annane [France] ; Pierre De Truchis [France]Source :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de survie (MeSH), Analyse multifactorielle (MeSH), Anti-infectieux (usage thérapeutique), Association médicamenteuse (MeSH), Azithromycine (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (pathogénicité), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (anatomopathologie), Infections à coronavirus (imagerie diagnostique), Infections à coronavirus (mortalité), Infections à coronavirus (traitement médicamenteux), Lopinavir (usage thérapeutique), Lymphocytes T (anatomopathologie), Lymphocytes T (virologie), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (imagerie diagnostique), Pneumopathie virale (mortalité), Pneumopathie virale (traitement médicamenteux), Pronostic (MeSH), Protéine C-réactive (métabolisme), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Tomodensitométrie (MeSH), Unités de soins intensifs (MeSH), Études rétrospectives (MeSH), Évolution de la maladie (MeSH).
- MESH :
- anatomopathologie : Infections à coronavirus, Lymphocytes T, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- imagerie diagnostique : Infections à coronavirus, Pneumopathie virale.
- mortalité : Infections à coronavirus, Pneumopathie virale.
- métabolisme : Protéine C-réactive.
- pathogénicité : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anti-infectieux, Azithromycine, Hydroxychloroquine, Lopinavir, Ritonavir.
- virologie : Lymphocytes T.
- Adulte, Adulte d'âge moyen, Analyse de survie, Analyse multifactorielle, Association médicamenteuse, Femelle, Humains, Mâle, Pandémies, Pronostic, Résultat thérapeutique, Sujet âgé, Tomodensitométrie, Unités de soins intensifs, Études rétrospectives, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Anti-Infective Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (pathogenicity), C-Reactive Protein (metabolism), Coronavirus Infections (diagnostic imaging), Coronavirus Infections (drug therapy), Coronavirus Infections (mortality), Coronavirus Infections (pathology), Disease Progression (MeSH), Drug Combinations (MeSH), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Intensive Care Units (MeSH), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Multivariate Analysis (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnostic imaging), Pneumonia, Viral (drug therapy), Pneumonia, Viral (mortality), Pneumonia, Viral (pathology), Prognosis (MeSH), Retrospective Studies (MeSH), Ritonavir (therapeutic use), Survival Analysis (MeSH), T-Lymphocytes (pathology), T-Lymphocytes (virology), Tomography, X-Ray Computed (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , metabolism : C-Reactive Protein.
- chemical , therapeutic use : Anti-Infective Agents, Azithromycin, Hydroxychloroquine, Lopinavir, Ritonavir.
- diagnostic imaging : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- pathology : Coronavirus Infections, Pneumonia, Viral, T-Lymphocytes.
- virology : T-Lymphocytes.
- Adult, Aged, Disease Progression, Drug Combinations, Female, Humans, Intensive Care Units, Male, Middle Aged, Multivariate Analysis, Pandemics, Prognosis, Retrospective Studies, Survival Analysis, Tomography, X-Ray Computed, Treatment Outcome.
Abstract
INTRODUCTION
The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated.
METHODS
Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5
RESULTS
A total of 132 patients were admitted: mean age 59.0±16.3 years; mean C-reactive protein (CRP) level 84.0±71.1 mg/L; 46% had a lymphocyte count <1000/mm
CONCLUSION
The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents.
DOI: 10.1016/j.ijantimicag.2020.106129
PubMed: 32755653
PubMed Central: PMC7396133
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.</title><author><name sortKey="Davido, Benjamin" sort="Davido, Benjamin" uniqKey="Davido B" first="Benjamin" last="Davido">Benjamin Davido</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France. Electronic address: benjamin.davido@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Boussaid, Ghilas" sort="Boussaid, Ghilas" uniqKey="Boussaid G" first="Ghilas" last="Boussaid">Ghilas Boussaid</name><affiliation wicri:level="3"><nlm:affiliation>Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Versailles</settlement></placeName></affiliation></author><author><name sortKey="Vaugier, Isabelle" sort="Vaugier, Isabelle" uniqKey="Vaugier I" first="Isabelle" last="Vaugier">Isabelle Vaugier</name><affiliation wicri:level="1"><nlm:affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Lansaman, Thibaud" sort="Lansaman, Thibaud" uniqKey="Lansaman T" first="Thibaud" last="Lansaman">Thibaud Lansaman</name><affiliation wicri:level="1"><nlm:affiliation>Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Bouchand, Frederique" sort="Bouchand, Frederique" uniqKey="Bouchand F" first="Frédérique" last="Bouchand">Frédérique Bouchand</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Lawrence, Christine" sort="Lawrence, Christine" uniqKey="Lawrence C" first="Christine" last="Lawrence">Christine Lawrence</name><affiliation wicri:level="1"><nlm:affiliation>EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Alvarez, Jean Claude" sort="Alvarez, Jean Claude" uniqKey="Alvarez J" first="Jean-Claude" last="Alvarez">Jean-Claude Alvarez</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Moine, Pierre" sort="Moine, Pierre" uniqKey="Moine P" first="Pierre" last="Moine">Pierre Moine</name><affiliation wicri:level="1"><nlm:affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Perronne, Veronique" sort="Perronne, Veronique" uniqKey="Perronne V" first="Véronique" last="Perronne">Véronique Perronne</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Barbot, Frederic" sort="Barbot, Frederic" uniqKey="Barbot F" first="Frédéric" last="Barbot">Frédéric Barbot</name><affiliation wicri:level="1"><nlm:affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Saleh Mghir, Azzam" sort="Saleh Mghir, Azzam" uniqKey="Saleh Mghir A" first="Azzam" last="Saleh-Mghir">Azzam Saleh-Mghir</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Perronne, Christian" sort="Perronne, Christian" uniqKey="Perronne C" first="Christian" last="Perronne">Christian Perronne</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Annane, Djillali" sort="Annane, Djillali" uniqKey="Annane D" first="Djillali" last="Annane">Djillali Annane</name><affiliation wicri:level="1"><nlm:affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="De Truchis, Pierre" sort="De Truchis, Pierre" uniqKey="De Truchis P" first="Pierre" last="De Truchis">Pierre De Truchis</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32755653</idno><idno type="pmid">32755653</idno><idno type="doi">10.1016/j.ijantimicag.2020.106129</idno><idno type="pmc">PMC7396133</idno><idno type="wicri:Area/Main/Corpus">000816</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000816</idno><idno type="wicri:Area/Main/Curation">000816</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000816</idno><idno type="wicri:Area/Main/Exploration">000816</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.</title><author><name sortKey="Davido, Benjamin" sort="Davido, Benjamin" uniqKey="Davido B" first="Benjamin" last="Davido">Benjamin Davido</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France. Electronic address: benjamin.davido@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Boussaid, Ghilas" sort="Boussaid, Ghilas" uniqKey="Boussaid G" first="Ghilas" last="Boussaid">Ghilas Boussaid</name><affiliation wicri:level="3"><nlm:affiliation>Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Versailles</settlement></placeName></affiliation></author><author><name sortKey="Vaugier, Isabelle" sort="Vaugier, Isabelle" uniqKey="Vaugier I" first="Isabelle" last="Vaugier">Isabelle Vaugier</name><affiliation wicri:level="1"><nlm:affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Lansaman, Thibaud" sort="Lansaman, Thibaud" uniqKey="Lansaman T" first="Thibaud" last="Lansaman">Thibaud Lansaman</name><affiliation wicri:level="1"><nlm:affiliation>Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Bouchand, Frederique" sort="Bouchand, Frederique" uniqKey="Bouchand F" first="Frédérique" last="Bouchand">Frédérique Bouchand</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Lawrence, Christine" sort="Lawrence, Christine" uniqKey="Lawrence C" first="Christine" last="Lawrence">Christine Lawrence</name><affiliation wicri:level="1"><nlm:affiliation>EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Alvarez, Jean Claude" sort="Alvarez, Jean Claude" uniqKey="Alvarez J" first="Jean-Claude" last="Alvarez">Jean-Claude Alvarez</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Moine, Pierre" sort="Moine, Pierre" uniqKey="Moine P" first="Pierre" last="Moine">Pierre Moine</name><affiliation wicri:level="1"><nlm:affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Perronne, Veronique" sort="Perronne, Veronique" uniqKey="Perronne V" first="Véronique" last="Perronne">Véronique Perronne</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Barbot, Frederic" sort="Barbot, Frederic" uniqKey="Barbot F" first="Frédéric" last="Barbot">Frédéric Barbot</name><affiliation wicri:level="1"><nlm:affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Saleh Mghir, Azzam" sort="Saleh Mghir, Azzam" uniqKey="Saleh Mghir A" first="Azzam" last="Saleh-Mghir">Azzam Saleh-Mghir</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Perronne, Christian" sort="Perronne, Christian" uniqKey="Perronne C" first="Christian" last="Perronne">Christian Perronne</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="Annane, Djillali" sort="Annane, Djillali" uniqKey="Annane D" first="Djillali" last="Annane">Djillali Annane</name><affiliation wicri:level="1"><nlm:affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author><author><name sortKey="De Truchis, Pierre" sort="De Truchis, Pierre" uniqKey="De Truchis P" first="Pierre" last="De Truchis">Pierre De Truchis</name><affiliation wicri:level="1"><nlm:affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches</wicri:regionArea><wicri:noRegion>Garches</wicri:noRegion><wicri:noRegion>Garches</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of antimicrobial agents</title><idno type="eISSN">1872-7913</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (pathogenicity)</term><term>C-Reactive Protein (metabolism)</term><term>Coronavirus Infections (diagnostic imaging)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (pathology)</term><term>Disease Progression (MeSH)</term><term>Drug Combinations (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Intensive Care Units (MeSH)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Multivariate Analysis (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnostic imaging)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (pathology)</term><term>Prognosis (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Survival Analysis (MeSH)</term><term>T-Lymphocytes (pathology)</term><term>T-Lymphocytes (virology)</term><term>Tomography, X-Ray Computed (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse de survie (MeSH)</term><term>Analyse multifactorielle (MeSH)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Azithromycine (usage thérapeutique)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (pathogénicité)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (imagerie diagnostique)</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Lopinavir (usage thérapeutique)</term><term>Lymphocytes T (anatomopathologie)</term><term>Lymphocytes T (virologie)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (anatomopathologie)</term><term>Pneumopathie virale (imagerie diagnostique)</term><term>Pneumopathie virale (mortalité)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pronostic (MeSH)</term><term>Protéine C-réactive (métabolisme)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Tomodensitométrie (MeSH)</term><term>Unités de soins intensifs (MeSH)</term><term>Études rétrospectives (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Lymphocytes T</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéine C-réactive</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term><term>Azithromycine</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Lymphocytes T</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Intensive Care Units</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Pandemics</term><term>Prognosis</term><term>Retrospective Studies</term><term>Survival Analysis</term><term>Tomography, X-Ray Computed</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Analyse multifactorielle</term><term>Association médicamenteuse</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tomodensitométrie</term><term>Unités de soins intensifs</term><term>Études rétrospectives</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 132 patients were admitted: mean age 59.0±16.3 years; mean C-reactive protein (CRP) level 84.0±71.1 mg/L; 46% had a lymphocyte count <1000/mm</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32755653</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of antimicrobial agents</Title><ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation></Journal><ArticleTitle>Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.</ArticleTitle><Pagination><MedlinePgn>106129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30312-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106129</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5<sup>th</sup> to April 25<sup>th</sup> 2020. Patient characteristics were compared between two periods (before/after March 19<sup>th</sup>) considering French guidelines. The aim of the study was to evaluate how medical care impacted unfavorable outcome, namely admission to intensive care unit (ICU) and/or death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 132 patients were admitted: mean age 59.0±16.3 years; mean C-reactive protein (CRP) level 84.0±71.1 mg/L; 46% had a lymphocyte count <1000/mm<sup>3</sup>. Prescribed anti-infective agents were lopinavir-ritonavir (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) (n=52). There was a significant decrease in ICU admission, from 43% to 12%, between the two periods (P<0.0001). Delays until transfer to ICU were similar between periods (P=0.86). Pulmonary computerized tomography (CT)-scans were performed significantly more often with time (from 50% to 90%, P<0.0001), and oxygen-dependency (53% vs 80%, P=0.001) and prescription of AZI±HCQ (from 25% to 76%, P<0.0001) were also greater over time. Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ (hazard ratio [HR]=0.45, 95% confidence interval [CI: 0.21-0.97], P=0.04), particularly among an identified category of individuals (lymphocyte ≥1000/mm<sup>3</sup> or CRP ≥100 mg/L).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davido</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France. Electronic address: benjamin.davido@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boussaid</LastName><ForeName>Ghilas</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaugier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lansaman</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchand</LastName><ForeName>Frédérique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moine</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perronne</LastName><ForeName>Véronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbot</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh-Mghir</LastName><ForeName>Azzam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perronne</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annane</LastName><ForeName>Djillali</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Truchis</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 RPC Team</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Antimicrob Agents</MedlineTA><NlmUniqueID>9111860</NlmUniqueID><ISSNLinking>0924-8579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">pneumonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32755653</ArticleId><ArticleId IdType="pii">S0924-8579(20)30312-5</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106129</ArticleId><ArticleId IdType="pmc">PMC7396133</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Versailles</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Davido, Benjamin" sort="Davido, Benjamin" uniqKey="Davido B" first="Benjamin" last="Davido">Benjamin Davido</name></noRegion><name sortKey="Alvarez, Jean Claude" sort="Alvarez, Jean Claude" uniqKey="Alvarez J" first="Jean-Claude" last="Alvarez">Jean-Claude Alvarez</name><name sortKey="Annane, Djillali" sort="Annane, Djillali" uniqKey="Annane D" first="Djillali" last="Annane">Djillali Annane</name><name sortKey="Barbot, Frederic" sort="Barbot, Frederic" uniqKey="Barbot F" first="Frédéric" last="Barbot">Frédéric Barbot</name><name sortKey="Bouchand, Frederique" sort="Bouchand, Frederique" uniqKey="Bouchand F" first="Frédérique" last="Bouchand">Frédérique Bouchand</name><name sortKey="Boussaid, Ghilas" sort="Boussaid, Ghilas" uniqKey="Boussaid G" first="Ghilas" last="Boussaid">Ghilas Boussaid</name><name sortKey="De Truchis, Pierre" sort="De Truchis, Pierre" uniqKey="De Truchis P" first="Pierre" last="De Truchis">Pierre De Truchis</name><name sortKey="Lansaman, Thibaud" sort="Lansaman, Thibaud" uniqKey="Lansaman T" first="Thibaud" last="Lansaman">Thibaud Lansaman</name><name sortKey="Lawrence, Christine" sort="Lawrence, Christine" uniqKey="Lawrence C" first="Christine" last="Lawrence">Christine Lawrence</name><name sortKey="Moine, Pierre" sort="Moine, Pierre" uniqKey="Moine P" first="Pierre" last="Moine">Pierre Moine</name><name sortKey="Perronne, Christian" sort="Perronne, Christian" uniqKey="Perronne C" first="Christian" last="Perronne">Christian Perronne</name><name sortKey="Perronne, Veronique" sort="Perronne, Veronique" uniqKey="Perronne V" first="Véronique" last="Perronne">Véronique Perronne</name><name sortKey="Saleh Mghir, Azzam" sort="Saleh Mghir, Azzam" uniqKey="Saleh Mghir A" first="Azzam" last="Saleh-Mghir">Azzam Saleh-Mghir</name><name sortKey="Vaugier, Isabelle" sort="Vaugier, Isabelle" uniqKey="Vaugier I" first="Isabelle" last="Vaugier">Isabelle Vaugier</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000500 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000500 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32755653
|texte= Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32755653" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |